Report error Found 408 Enz. Inhib. hit(s) with all data for entry = 12867
TargetReceptor tyrosine-protein kinase erbB-2 [V777L](Homo sapiens (Human))
Cogent Biosciences
US Patent
Cogent Biosciences
US Patent
Affinity DataIC50: 50nMAssay Description:In vitro enzyme assays based on CisBio HTRF-KinEASE-TK technology were used to determine compound potencies. EGFR WT (Invitrogen, cat #PR7295B) at 0....More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [V777L](Homo sapiens (Human))
Cogent Biosciences
US Patent
Cogent Biosciences
US Patent
Affinity DataIC50: 50nMAssay Description:In vitro enzyme assays based on CisBio HTRF-KinEASE-TK technology were used to determine compound potencies. EGFR WT (Invitrogen, cat #PR7295B) at 0....More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [V777L](Homo sapiens (Human))
Cogent Biosciences
US Patent
Cogent Biosciences
US Patent
Affinity DataIC50: 50nMAssay Description:In vitro enzyme assays based on CisBio HTRF-KinEASE-TK technology were used to determine compound potencies. EGFR WT (Invitrogen, cat #PR7295B) at 0....More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [V777L](Homo sapiens (Human))
Cogent Biosciences
US Patent
Cogent Biosciences
US Patent
Affinity DataIC50: 50nMAssay Description:In vitro enzyme assays based on CisBio HTRF-KinEASE-TK technology were used to determine compound potencies. EGFR WT (Invitrogen, cat #PR7295B) at 0....More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [V777L](Homo sapiens (Human))
Cogent Biosciences
US Patent
Cogent Biosciences
US Patent
Affinity DataIC50: 50nMAssay Description:In vitro enzyme assays based on CisBio HTRF-KinEASE-TK technology were used to determine compound potencies. EGFR WT (Invitrogen, cat #PR7295B) at 0....More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [V777L](Homo sapiens (Human))
Cogent Biosciences
US Patent
Cogent Biosciences
US Patent
Affinity DataIC50: 50nMAssay Description:In vitro enzyme assays based on CisBio HTRF-KinEASE-TK technology were used to determine compound potencies. EGFR WT (Invitrogen, cat #PR7295B) at 0....More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [V777L](Homo sapiens (Human))
Cogent Biosciences
US Patent
Cogent Biosciences
US Patent
Affinity DataIC50: 50nMAssay Description:In vitro enzyme assays based on CisBio HTRF-KinEASE-TK technology were used to determine compound potencies. EGFR WT (Invitrogen, cat #PR7295B) at 0....More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [V777L](Homo sapiens (Human))
Cogent Biosciences
US Patent
Cogent Biosciences
US Patent
Affinity DataIC50: 50nMAssay Description:In vitro enzyme assays based on CisBio HTRF-KinEASE-TK technology were used to determine compound potencies. EGFR WT (Invitrogen, cat #PR7295B) at 0....More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [V777L](Homo sapiens (Human))
Cogent Biosciences
US Patent
Cogent Biosciences
US Patent
Affinity DataIC50: 50nMAssay Description:In vitro enzyme assays based on CisBio HTRF-KinEASE-TK technology were used to determine compound potencies. EGFR WT (Invitrogen, cat #PR7295B) at 0....More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [V777L](Homo sapiens (Human))
Cogent Biosciences
US Patent
Cogent Biosciences
US Patent
Affinity DataIC50: 50nMAssay Description:In vitro enzyme assays based on CisBio HTRF-KinEASE-TK technology were used to determine compound potencies. EGFR WT (Invitrogen, cat #PR7295B) at 0....More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [V777L](Homo sapiens (Human))
Cogent Biosciences
US Patent
Cogent Biosciences
US Patent
Affinity DataIC50: 50nMAssay Description:In vitro enzyme assays based on CisBio HTRF-KinEASE-TK technology were used to determine compound potencies. EGFR WT (Invitrogen, cat #PR7295B) at 0....More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [V777L](Homo sapiens (Human))
Cogent Biosciences
US Patent
Cogent Biosciences
US Patent
Affinity DataIC50: 50nMAssay Description:In vitro enzyme assays based on CisBio HTRF-KinEASE-TK technology were used to determine compound potencies. EGFR WT (Invitrogen, cat #PR7295B) at 0....More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [V777L](Homo sapiens (Human))
Cogent Biosciences
US Patent
Cogent Biosciences
US Patent
Affinity DataIC50: 50nMAssay Description:In vitro enzyme assays based on CisBio HTRF-KinEASE-TK technology were used to determine compound potencies. EGFR WT (Invitrogen, cat #PR7295B) at 0....More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [V777L](Homo sapiens (Human))
Cogent Biosciences
US Patent
Cogent Biosciences
US Patent
Affinity DataIC50: 50nMAssay Description:In vitro enzyme assays based on CisBio HTRF-KinEASE-TK technology were used to determine compound potencies. EGFR WT (Invitrogen, cat #PR7295B) at 0....More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [V777L](Homo sapiens (Human))
Cogent Biosciences
US Patent
Cogent Biosciences
US Patent
Affinity DataIC50: 50nMAssay Description:In vitro enzyme assays based on CisBio HTRF-KinEASE-TK technology were used to determine compound potencies. EGFR WT (Invitrogen, cat #PR7295B) at 0....More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [V777L](Homo sapiens (Human))
Cogent Biosciences
US Patent
Cogent Biosciences
US Patent
Affinity DataIC50: 50nMAssay Description:In vitro enzyme assays based on CisBio HTRF-KinEASE-TK technology were used to determine compound potencies. EGFR WT (Invitrogen, cat #PR7295B) at 0....More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [V777L](Homo sapiens (Human))
Cogent Biosciences
US Patent
Cogent Biosciences
US Patent
Affinity DataIC50: 50nMAssay Description:In vitro enzyme assays based on CisBio HTRF-KinEASE-TK technology were used to determine compound potencies. EGFR WT (Invitrogen, cat #PR7295B) at 0....More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [V777L](Homo sapiens (Human))
Cogent Biosciences
US Patent
Cogent Biosciences
US Patent
Affinity DataIC50: 50nMAssay Description:In vitro enzyme assays based on CisBio HTRF-KinEASE-TK technology were used to determine compound potencies. EGFR WT (Invitrogen, cat #PR7295B) at 0....More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [V777L](Homo sapiens (Human))
Cogent Biosciences
US Patent
Cogent Biosciences
US Patent
Affinity DataIC50: 50nMAssay Description:In vitro enzyme assays based on CisBio HTRF-KinEASE-TK technology were used to determine compound potencies. EGFR WT (Invitrogen, cat #PR7295B) at 0....More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [V777L](Homo sapiens (Human))
Cogent Biosciences
US Patent
Cogent Biosciences
US Patent
Affinity DataIC50: 50nMAssay Description:In vitro enzyme assays based on CisBio HTRF-KinEASE-TK technology were used to determine compound potencies. EGFR WT (Invitrogen, cat #PR7295B) at 0....More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [V777L](Homo sapiens (Human))
Cogent Biosciences
US Patent
Cogent Biosciences
US Patent
Affinity DataIC50: 50nMAssay Description:In vitro enzyme assays based on CisBio HTRF-KinEASE-TK technology were used to determine compound potencies. EGFR WT (Invitrogen, cat #PR7295B) at 0....More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [V777L](Homo sapiens (Human))
Cogent Biosciences
US Patent
Cogent Biosciences
US Patent
Affinity DataIC50: 50nMAssay Description:In vitro enzyme assays based on CisBio HTRF-KinEASE-TK technology were used to determine compound potencies. EGFR WT (Invitrogen, cat #PR7295B) at 0....More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [V777L](Homo sapiens (Human))
Cogent Biosciences
US Patent
Cogent Biosciences
US Patent
Affinity DataIC50: 50nMAssay Description:In vitro enzyme assays based on CisBio HTRF-KinEASE-TK technology were used to determine compound potencies. EGFR WT (Invitrogen, cat #PR7295B) at 0....More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [V777L](Homo sapiens (Human))
Cogent Biosciences
US Patent
Cogent Biosciences
US Patent
Affinity DataIC50: 50nMAssay Description:In vitro enzyme assays based on CisBio HTRF-KinEASE-TK technology were used to determine compound potencies. EGFR WT (Invitrogen, cat #PR7295B) at 0....More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [V777L](Homo sapiens (Human))
Cogent Biosciences
US Patent
Cogent Biosciences
US Patent
Affinity DataIC50: 50nMAssay Description:In vitro enzyme assays based on CisBio HTRF-KinEASE-TK technology were used to determine compound potencies. EGFR WT (Invitrogen, cat #PR7295B) at 0....More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [V777L](Homo sapiens (Human))
Cogent Biosciences
US Patent
Cogent Biosciences
US Patent
Affinity DataIC50: 50nMAssay Description:In vitro enzyme assays based on CisBio HTRF-KinEASE-TK technology were used to determine compound potencies. EGFR WT (Invitrogen, cat #PR7295B) at 0....More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [V777L](Homo sapiens (Human))
Cogent Biosciences
US Patent
Cogent Biosciences
US Patent
Affinity DataIC50: 50nMAssay Description:In vitro enzyme assays based on CisBio HTRF-KinEASE-TK technology were used to determine compound potencies. EGFR WT (Invitrogen, cat #PR7295B) at 0....More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [V777L](Homo sapiens (Human))
Cogent Biosciences
US Patent
Cogent Biosciences
US Patent
Affinity DataIC50: 50nMAssay Description:In vitro enzyme assays based on CisBio HTRF-KinEASE-TK technology were used to determine compound potencies. EGFR WT (Invitrogen, cat #PR7295B) at 0....More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [V777L](Homo sapiens (Human))
Cogent Biosciences
US Patent
Cogent Biosciences
US Patent
Affinity DataIC50: 50nMAssay Description:In vitro enzyme assays based on CisBio HTRF-KinEASE-TK technology were used to determine compound potencies. EGFR WT (Invitrogen, cat #PR7295B) at 0....More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [V777L](Homo sapiens (Human))
Cogent Biosciences
US Patent
Cogent Biosciences
US Patent
Affinity DataIC50: 50nMAssay Description:In vitro enzyme assays based on CisBio HTRF-KinEASE-TK technology were used to determine compound potencies. EGFR WT (Invitrogen, cat #PR7295B) at 0....More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [V777L](Homo sapiens (Human))
Cogent Biosciences
US Patent
Cogent Biosciences
US Patent
Affinity DataIC50: 50nMAssay Description:In vitro enzyme assays based on CisBio HTRF-KinEASE-TK technology were used to determine compound potencies. EGFR WT (Invitrogen, cat #PR7295B) at 0....More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [V777L](Homo sapiens (Human))
Cogent Biosciences
US Patent
Cogent Biosciences
US Patent
Affinity DataIC50: 50nMAssay Description:In vitro enzyme assays based on CisBio HTRF-KinEASE-TK technology were used to determine compound potencies. EGFR WT (Invitrogen, cat #PR7295B) at 0....More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [V777L](Homo sapiens (Human))
Cogent Biosciences
US Patent
Cogent Biosciences
US Patent
Affinity DataIC50: 50nMAssay Description:In vitro enzyme assays based on CisBio HTRF-KinEASE-TK technology were used to determine compound potencies. EGFR WT (Invitrogen, cat #PR7295B) at 0....More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [V777L](Homo sapiens (Human))
Cogent Biosciences
US Patent
Cogent Biosciences
US Patent
Affinity DataIC50: 50nMAssay Description:In vitro enzyme assays based on CisBio HTRF-KinEASE-TK technology were used to determine compound potencies. EGFR WT (Invitrogen, cat #PR7295B) at 0....More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [V777L](Homo sapiens (Human))
Cogent Biosciences
US Patent
Cogent Biosciences
US Patent
Affinity DataIC50: 50nMAssay Description:In vitro enzyme assays based on CisBio HTRF-KinEASE-TK technology were used to determine compound potencies. EGFR WT (Invitrogen, cat #PR7295B) at 0....More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [V777L](Homo sapiens (Human))
Cogent Biosciences
US Patent
Cogent Biosciences
US Patent
Affinity DataIC50: 50nMAssay Description:In vitro enzyme assays based on CisBio HTRF-KinEASE-TK technology were used to determine compound potencies. EGFR WT (Invitrogen, cat #PR7295B) at 0....More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [V777L](Homo sapiens (Human))
Cogent Biosciences
US Patent
Cogent Biosciences
US Patent
Affinity DataIC50: 50nMAssay Description:In vitro enzyme assays based on CisBio HTRF-KinEASE-TK technology were used to determine compound potencies. EGFR WT (Invitrogen, cat #PR7295B) at 0....More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [V777L](Homo sapiens (Human))
Cogent Biosciences
US Patent
Cogent Biosciences
US Patent
Affinity DataIC50: 50nMAssay Description:In vitro enzyme assays based on CisBio HTRF-KinEASE-TK technology were used to determine compound potencies. EGFR WT (Invitrogen, cat #PR7295B) at 0....More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [V777L](Homo sapiens (Human))
Cogent Biosciences
US Patent
Cogent Biosciences
US Patent
Affinity DataIC50: 50nMAssay Description:In vitro enzyme assays based on CisBio HTRF-KinEASE-TK technology were used to determine compound potencies. EGFR WT (Invitrogen, cat #PR7295B) at 0....More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [V777L](Homo sapiens (Human))
Cogent Biosciences
US Patent
Cogent Biosciences
US Patent
Affinity DataIC50: 50nMAssay Description:In vitro enzyme assays based on CisBio HTRF-KinEASE-TK technology were used to determine compound potencies. EGFR WT (Invitrogen, cat #PR7295B) at 0....More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [V777L](Homo sapiens (Human))
Cogent Biosciences
US Patent
Cogent Biosciences
US Patent
Affinity DataIC50: 50nMAssay Description:In vitro enzyme assays based on CisBio HTRF-KinEASE-TK technology were used to determine compound potencies. EGFR WT (Invitrogen, cat #PR7295B) at 0....More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [V777L](Homo sapiens (Human))
Cogent Biosciences
US Patent
Cogent Biosciences
US Patent
Affinity DataIC50: 50nMAssay Description:In vitro enzyme assays based on CisBio HTRF-KinEASE-TK technology were used to determine compound potencies. EGFR WT (Invitrogen, cat #PR7295B) at 0....More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [V777L](Homo sapiens (Human))
Cogent Biosciences
US Patent
Cogent Biosciences
US Patent
Affinity DataIC50: 50nMAssay Description:In vitro enzyme assays based on CisBio HTRF-KinEASE-TK technology were used to determine compound potencies. EGFR WT (Invitrogen, cat #PR7295B) at 0....More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [V777L](Homo sapiens (Human))
Cogent Biosciences
US Patent
Cogent Biosciences
US Patent
Affinity DataIC50: 50nMAssay Description:In vitro enzyme assays based on CisBio HTRF-KinEASE-TK technology were used to determine compound potencies. EGFR WT (Invitrogen, cat #PR7295B) at 0....More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [V777L](Homo sapiens (Human))
Cogent Biosciences
US Patent
Cogent Biosciences
US Patent
Affinity DataIC50: 50nMAssay Description:In vitro enzyme assays based on CisBio HTRF-KinEASE-TK technology were used to determine compound potencies. EGFR WT (Invitrogen, cat #PR7295B) at 0....More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [V777L](Homo sapiens (Human))
Cogent Biosciences
US Patent
Cogent Biosciences
US Patent
Affinity DataIC50: 50nMAssay Description:In vitro enzyme assays based on CisBio HTRF-KinEASE-TK technology were used to determine compound potencies. EGFR WT (Invitrogen, cat #PR7295B) at 0....More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [V777L](Homo sapiens (Human))
Cogent Biosciences
US Patent
Cogent Biosciences
US Patent
Affinity DataIC50: 50nMAssay Description:In vitro enzyme assays based on CisBio HTRF-KinEASE-TK technology were used to determine compound potencies. EGFR WT (Invitrogen, cat #PR7295B) at 0....More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [V777L](Homo sapiens (Human))
Cogent Biosciences
US Patent
Cogent Biosciences
US Patent
Affinity DataIC50: 50nMAssay Description:In vitro enzyme assays based on CisBio HTRF-KinEASE-TK technology were used to determine compound potencies. EGFR WT (Invitrogen, cat #PR7295B) at 0....More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [V777L](Homo sapiens (Human))
Cogent Biosciences
US Patent
Cogent Biosciences
US Patent
Affinity DataIC50: 50nMAssay Description:In vitro enzyme assays based on CisBio HTRF-KinEASE-TK technology were used to determine compound potencies. EGFR WT (Invitrogen, cat #PR7295B) at 0....More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [V777L](Homo sapiens (Human))
Cogent Biosciences
US Patent
Cogent Biosciences
US Patent
Affinity DataIC50: 50nMAssay Description:In vitro enzyme assays based on CisBio HTRF-KinEASE-TK technology were used to determine compound potencies. EGFR WT (Invitrogen, cat #PR7295B) at 0....More data for this Ligand-Target Pair

















































